f Post-Approval Studies (PAS) Database
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

CP22-01 Postmarket Evaluation of the EVO ICL


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Progress Adequate
Application Number /
Requirement Number
P030016 S035/ PAS002
Date Original Protocol Accepted 05/20/2022
Date Current Protocol Accepted  
Study Name CP22-01 Postmarket Evaluation of the EVO ICL
Device Name EVO/EVO+VISIAN Implantable Collamer Lens
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Historical Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives This new enrollment, prospective, multi-center, single arm PAS study will be conducted at up to 10 clinical sites in the United States (US). The study is designed to evaluate the success of the EVO Physician Certification Program in reducing the rate of early IOP increases at 1 – 6 hours after implantation of EVO/EVO+ ICL lenses by surgeons who have been trained and certified under the EVO Physician Certification Program.
Study Population Subjects aged 21 to 45 years implanted with EVO/EVO+ ICLs in both eyes, in accordance with the product labeling and the eligibility criteria.
Sample Size The study will enroll a minimum 200 subjects (i.e., 200 primary eyes and 200 fellow eyes).
Assumptions include:
• The proportion of primary eyes that will reach or exceed an IOP of 30 mmHg is 6% and the proportion of primary eyes that will reach or exceed an IOP of 40 mmHg is 1%. These estimates are based on Study CP19-01 data (as presented in PMA P030016/S035) from investigators who followed the instructions in the proposed EVO Physician Certification Program regarding removal of OVD, i.e., used a minimum of 10 – 20 cc of irrigation solution.
• The proportion of fellow eyes reaching these thresholds for increased IOP will be equivalent to the rates found in the primary eyes.
• No more than 10% loss to follow-up in this 2-week study.
For a single sample exact binomial test with a two-tailed alpha of 0.05 to demonstrate that a hypothesized rate of 6% is significantly lower than 15.3% for IOP spikes = 30 mmHg with 98% power, a sample of 181 eyes would be required. Demonstrating that the rate of IOP spikes greater than or equal to 40 mmHg is significantly lower, given a hypothesized rate of 1% vs the Study CP19-01 rate of 7%, a sample size of 181 primary eyes of 181 subjects will achieve 96% power. Power to achieve both endpoints can be conservatively estimated by the product of the two powers, .98 times .96, or 94%. Analysis of fellow eye rates would also be conducted, and results would be used to support the findings of the two primary eye analyses.
Key Study Endpoints The primary endpoint is the proportion of primary (i.e., first implanted) eyes that have IOP greater than or equal to 30 mmHg and IOP greater than or equal to 40 mmHg at 1 – 6 hours postoperatively.
The secondary endpoint is the proportion of fellow eyes that have IOP greater than or equal to 30 mmHg and IOP greater than or equal to 40 mmHg at 1 – 6 hours postoperatively.
Other safety endpoints include the following:
1) the proportion of fellow eyes that have IOP greater than or equal to 30 mmHg at 1 - 6 hours postoperatively
2) the proportion of fellow eyes that have IOP greater than or equal to 40 mmHg at 1 - 6 hours postoperatively
3) Rates of increased IOP in primary and all (primary + fellow) eyes attributed to retained OVD
4) Rates of increased IOP in primary and all eyes attributed to other causes (e.g., pupillary block, steroid response, etc.)
5) Rates of all categories of AEs (in primary and in all eyes)
6) Device deficiencies
7) Distribution of lens vault measured by OCT
8) Slit lamp findings and distributions of gradings (e.g., of anterior chamber cells and flare)
9) Notable ophthalmoscopy findings
10) UDVA and CDVA (uncorrected and corrected distance visual acuity)
11) Instances of loss of greater than or equal to 10 letters of CDVA from baseline, along with analyses of the causes.
Follow-up Visits and Length of Follow-up Length of follow-up will be two weeks post-implantation of the fellow eye
Interim or Final Data Summary
Interim Results N/A
Actual Number of Patients Enrolled 0
Actual Number of Sites Enrolled 7
Patient Follow-up Rate N/A
Study Strengths & Weaknesses N/A


CP22-01 Postmarket Evaluation of the EVO ICL Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
6 month report 09/23/2022 09/21/2022 On Time
1 year report 03/25/2023    
18 month report 09/23/2023    
2 year report 03/24/2024    
3 year report 03/24/2025    


Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-